When Devex and PSI partnered to survey experts on what constitutes a “best buy” for global health, strengthening health systems rose to the top of the list.
But as funding agencies and policymakers demand more and more evidence of impact for every development dollar spent, the pressure is on health care providers to prove value-for-money through measurements like “patients treated” or “vaccines delivered.”
Devex Editor Rolf Rosenkranz sat down with PSI President and CEO Karl Hofmann to learn how his organization is exploring “unconventional financing” options to sustain funding for health outcomes in the developing world.
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Michael Igoe@AlterIgoe
Michael Igoe is a Senior Reporter with Devex, based in Washington, D.C. He covers U.S. foreign aid, global health, climate change, and development finance. Prior to joining Devex, Michael researched water management and climate change adaptation in post-Soviet Central Asia, where he also wrote for EurasiaNet. Michael earned his bachelor's degree from Bowdoin College, where he majored in Russian, and his master’s degree from the University of Montana, where he studied international conservation and development.